You just read:

FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

News provided by

Janssen Biotech, Inc.

Aug 02, 2017, 16:49 ET